In: Non-small cell lung cancer

Ruzaltatug rezetecan

Hengrui · SHR-A2009

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
6 active
9 in total
Targets
 

What this is

How it works
HER3-targeted antibody-drug conjugate
How it’s given
“SHR-A2009 monotherapy ,SHR-A2009 will be administered intravenously”In the company’s words, NCT06671379 on ClinicalTrials.gov
Tested for
Non-small Cell Lung Cancer (3 trials), Advanced Solid Tumors (2 trials), Non-squamous Non-small Cell Lung Cancer
Main trialPhase 3
“This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.”In the company’s words, NCT06671379 on ClinicalTrials.gov
Other names
SHR-A2009

Other drugs for Non-small Cell Lung Cancer

All 561 drugs for Non-small Cell Lung Cancer

Coming up6

Changes1

Last 90 days

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2026 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Phase 3Not yet recruiting 30 Dec 2028 SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
Phase 3Active, not recruiting Nov 2032 A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Phase 2Recruiting 30 Dec 2028 An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
Phase 1/2Recruiting Jun 2029 A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Phase 1Active, not recruiting 30 Dec 2026 A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
Phase 1/2Unknown Dec 2025 A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
Phase 1/2Unknown 31 Oct 2026 Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
Phase 1Completed 30 Apr 2024 The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ruzaltatug rezetecan

Following is part of Solo: you see every change to Ruzaltatug rezetecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in